Biomarkers of Esophageal Adenocarcinoma and Barrett’s Esophagus
Open Access
- 1 March 2004
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (5) , 1561-1569
- https://doi.org/10.1158/0008-5472.can-03-2438
Abstract
Pigment epithelium-derived factor (PEDF) is expressed in several normal organs and identified as an inhibitor of neovascularization. In the present study, we screened the expression of PEDF immunohistochemically and investigated its correlation with clinicopathological features in patients who underwent surgery for ductal pancreatic adenocarcinoma. Of the 80 patients, 22 cases (27.5%) were positive for PEDF. A significant association was found between the PEDF expression and low microvessel density (P = 0.0003). No correlation was found between PEDF expression and age, gender, depth of invasion, tumor diameter, lymphatic invasion, venous, invasion or histopathological grading. The patients in pathological stage II had a significantly higher incidence of PEDF-positive expression than those in pathological stage III or IVA (P = 0.0418). PEDF immunoreactivity was inversely associated with liver metastasis (P = 0.0422). The survival of patients that were PEDF positive was significantly longer than that of those with negative expression (P = 0.0026). Multivariate analysis using the Cox regression model indicated that PEDF-positive expression was an independent favorable prognostic factor (risk ratio, 0.394; P = 0.0016). We conclude that PEDF expression suggests a more favorable prognosis than in patients whose carcinomas lack PEDF expression.Keywords
This publication has 102 references indexed in Scilit:
- Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adultsGut, 2002
- The Effect of Selective Cyclooxygenase-2 Inhibition in Barrett's Esophagus Epithelium: An In Vitro StudyJNCI Journal of the National Cancer Institute, 2002
- Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarraysOncogene, 2002
- Endoscopic Mapping and Surrogate Markers for Better Surveillance in Barrett EsophagusAmerican Journal of Clinical Pathology, 2000
- Barrettʼs oesophagusEuropean Journal of Gastroenterology & Hepatology, 2000
- Qualitative mapping of Barrett’s metaplasia: a prerequisite for intervention trialsGastrointestinal Endoscopy, 1999
- Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomasMolecular Carcinogenesis, 1998
- Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancersHuman Molecular Genetics, 1995
- The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequenceSurgical Oncology, 1995
- The Incidence of Adenocarcinoma in Columnar-Lined (Barrett's) EsophagusNew England Journal of Medicine, 1985